Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezo + tiragolumab + XELOX in HER2-negative advanced gastric/GEJ cancer (China)
CTR20211614Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab, atezolizumab, oxaliplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Roche. Primary endpoint: Objective response rate (ORR). Started Jul 2021; status: completed.
02
Drugs
tiragolumabatezolizumaboxaliplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20211614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211614.